{"id":"W4283576570","doi":"10.1136/annrheumdis-2022-eular.2441","title":"OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; University Health Network","funders":"UCB Pharma; Sahlgrenska Akademin; Universitätsspital Zürich; Diakonhjemmet; Universidade de Lisboa; Amsterdam University Medical Centers; Univerzita Karlova v Praze; Göteborgs Universitet; Vrije Universiteit Amsterdam; Dokuz Eylül Üniversitesi; Lunds Universitet; Skånes universitetssjukhus; Universität Zürich; Radboud Universiteit; University of Aberdeen; Helsingin Yliopisto; Háskóli Íslands; Aarhus Universitet; Aarhus Universitetshospital","keywords":"Medicine; Ankylosing spondylitis; Placebo; Clinical endpoint; BASDAI; Internal medicine; Mallinckrodt; Surgery; Gastroenterology; Randomized controlled trial; Arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001830405,0.001638111,0.003422888,0.0004904877,0.0004863681,0.001255436,0.0008581823,0.002041664,0.005581069],"category_scores_gemma":[0.001528084,0.0007982974,0.00249365,0.0004129483,0.001069008,0.001381778,0.0004372058,0.003145393,0.001080694],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000536589,"about_ca_system_score_gemma":0.0009298482,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006658343,"about_ca_topic_score_gemma":0.001431236,"domain_scores_codex":[0.9993783,0.0002759035,0.00004561649,0.0001063806,0.00007622892,0.0001174475],"domain_scores_gemma":[0.9991158,0.0002498765,0.0002322858,0.00006811441,0.00005980204,0.0002741996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9656985,0.006856515,0.001088286,0.0009620321,0.001183926,0.00006283224,0.00005815733,0.0002237224,0.00340157,0.00006088463,0.0008551066,0.01954838],"study_design_scores_gemma":[0.926961,0.06663129,0.004730418,0.00004448828,0.0005521692,0.00004511463,0.00002834214,0.0001886036,0.0003198236,0.00006191525,0.0004185492,0.00001830255],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9861984,0.008180453,0.000367298,0.000620277,0.0003601087,0.001466405,0.001027601,0.0001020976,0.00167732],"genre_scores_gemma":[0.9872413,0.004075766,0.0009469857,0.001193501,0.0006440599,0.001709513,0.001349915,0.00002624389,0.002812647],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005581069,"threshold_uncertainty_score":0.01867056,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02652728134866949,"score_gpt":0.3033886283584113,"score_spread":0.2768613470097418,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}